STOCK TITAN

Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Antibe Therapeutics Inc. faces an unexpected setback as the arbitrator rules in favor of Nuance Pharma, rescinding the license agreement for otenaproxesul commercialization in Greater China. Antibe must refund US$20 million upfront payment and pay approximately US$4 million in interest and costs. The decision is final and not subject to appeal, impacting the company's short-term plans and development timelines. Despite the setback, Antibe remains committed to advancing otenaproxesul based on positive clinical results.
Positive
  • None.
Negative
  • Antibe Therapeutics faces an unexpected setback as the arbitrator rules in favor of Nuance Pharma, rescinding the license agreement for otenaproxesul commercialization in Greater China. Antibe must refund US$20 million upfront payment and pay approximately US$4 million in interest and costs. The decision is final and not subject to appeal, impacting the company's short-term plans and development timelines.

TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, today announced that the arbitrator has found in favor of Nuance Pharma in the dispute regarding the license agreement for the commercialization of otenaproxesul in the Greater China region. The confidential ruling from the Singapore International Arbitration Centre rescinds the license agreement and requires Antibe to refund the US$20 million upfront payment and pay interest and costs of approximately US$4 million. The decision is not subject to appeal. Antibe views this unexpected result as highly unusual based on best practices for licensing deals in the biotech industry.

“We strongly disagree with this decision,” commented Dan Legault, Antibe’s CEO. “Nonetheless, we acknowledge the fact that we agreed to binding arbitration in a foreign jurisdiction. Antibe respects the confidentiality and final nature of the arbitration proceedings and will accept the decision in good faith. We continue to believe that the comprehensive data package shared with Nuance for the previous chronic pain formulation fully reflected the drug’s safety and efficacy characteristics. Although this ruling presents a significant short-term challenge, we remain committed to developing otenaproxesul -- particularly due to the strength of recent clinical results for acute pain that have significantly de-risked its final trials.”

In light of the arbitral ruling, the Company is evaluating its development and milestone plans for the balance of 2024, which may include adjusting timelines as circumstances require. The strong data from the recent PK/PD study highlight otenaproxesul’s potential and the priority remains conducting the Phase II trial as soon as possible. More information will be shared as the Company determines the best path forward for all stakeholders.

About Antibe Therapeutics Inc.

Antibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation therapies to target pain and inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today’s NSAIDs for acute pain. Antibe’s second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

Forward Looking Statements

This news release includes certain forward-looking statements under applicable securities laws, which may include, but are not limited to, statements concerning the payment of amounts due to Nuance under the arbitral award, the anticipated scope, timing, duration and completion of certain of the Company’s pre-clinical and clinical trial programs and studies and the anticipated timing for seeking market approval for certain of the Company’s drugs and therapies for certain additional indications. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar wording. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s inability to timely execute on its business strategy and timely and successfully complete its clinical trials and studies, the Company’s inability to obtain the necessary regulatory approvals related to its activities, risks associated with drug development generally and those risk factors set forth in the Company’s public filings made in Canada and available on sedarplus.com. The Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Antibe Therapeutics Inc.

Christina Cameron

VP Investor Relations

+1 416-577-1443

christina@antibethera.com

Source: Antibe Therapeutics Inc.

FAQ

What is the impact of the arbitrator's ruling on Antibe Therapeutics Inc.?

The arbitrator's ruling in favor of Nuance Pharma rescinds the license agreement for otenaproxesul commercialization in Greater China, requiring Antibe to refund US$20 million upfront payment and pay approximately US$4 million in interest and costs.

What is the response of Antibe's CEO to the arbitrator's decision?

Antibe's CEO, Dan Legault, strongly disagrees with the arbitrator's decision but acknowledges the binding arbitration in a foreign jurisdiction. The company respects the finality of the ruling and plans to accept it in good faith.

How does Antibe plan to move forward after the arbitrator's decision?

Antibe is evaluating its development and milestone plans for the balance of 2024 in light of the arbitrator's ruling. The company may adjust timelines as needed and remains committed to advancing otenaproxesul based on positive clinical results.

What is the significance of the recent PK/PD study for otenaproxesul?

The strong data from the recent PK/PD study highlights otenaproxesul's potential, and the priority for Antibe remains conducting the Phase II trial as soon as possible.

What is the current status of the license agreement between Antibe and Nuance Pharma?

The license agreement for the commercialization of otenaproxesul in the Greater China region has been rescinded by the arbitrator in favor of Nuance Pharma, leading to financial implications for Antibe.

ANTIBE THERAPEUTICS INC

OTC:ATBPF

ATBPF Rankings

ATBPF Latest News

ATBPF Stock Data

11.45M
47.69M
7.94%
Biotechnology
Healthcare
Link
United States of America
Toronto